Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 10:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 968 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Stage IV Gastrointestinal Cancer Clear all
Completed Phase 1Phase 2 Interventional

Remote Resistance Exercise Powering Survivors - Gastrointestinal Oncology

NCT05664178
View directory record Official record
Conditions
Gastrointestinal Cancer
Interventions
Tele-Resistance Training
Behavioral
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 20, 2026, 10:14 PM EDT
Terminated Phase 1Phase 2 Interventional

SU011248 in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Stage IV Colorectal Cancer

NCT00361244
View directory record Official record
Conditions
Colorectal Carcinoma
Interventions
SU011248, Irinotecan, Cetuximab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 17, 2017 · Synced Oct 20, 2026, 10:14 PM EDT
Terminated Phase 1 Interventional

S0114 Vaccine Therapy in Treating Patients With Gastric, Prostate, or Ovarian Cancer

NCT00023634
View directory record Official record
Conditions
Brain Tumors, Gastric Cancer, Ovarian Cancer, Prostate Cancer
Interventions
KLH, GMCSF
Biological
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
13
States / cities
Bay City, Michigan • Port Huron, Michigan • Bellingham, Washington + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 20, 2026, 10:14 PM EDT
Completed Phase 2 Interventional Results available

Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer

NCT01178944
View directory record Official record
Conditions
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Undifferentiated Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Recurrent Esophageal Adenocarcinoma, Recurrent Esophageal Squamous Cell Carcinoma, Recurrent Gastric Carcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IIIB Esophageal Squamous Cell Carcinoma, Stage IIIB Gastric Cancer, Stage IIIC Esophageal Adenocarcinoma, Stage IIIC Esophageal Squamous Cell Carcinoma, Stage IIIC Gastric Cancer, Stage IV Esophageal Adenocarcinoma, Stage IV Esophageal Squamous Cell Carcinoma, Stage IV Gastric Cancer, Undifferentiated Gastric Carcinoma
Interventions
Laboratory Biomarker Analysis, Oxaliplatin, Pralatrexate
Other · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Buffalo, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Oct 20, 2026, 10:14 PM EDT
Completed No phase listed Observational

Studying Pain and Symptom Distress in Patients With Advanced Colon Cancer, Rectal Cancer, Pancreatic Cancer, or Liver Cancer

NCT00950144
View directory record Official record
Conditions
Colorectal Cancer, Depression, Fatigue, Liver Cancer, Pain, Pancreatic Cancer
Interventions
medical chart review, questionnaire administration, study of socioeconomic and demographic variables, quality-of-life assessment
Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2011 · Synced Oct 20, 2026, 10:14 PM EDT
Completed Phase 2 Interventional Results available

Cetuximab & Celecoxib for Metastatic Colorectal Cancer or Colorectal Cancer That Cannot Be Removed by Surgery

NCT00466505
View directory record Official record
Conditions
Colorectal Cancer
Interventions
cetuximab, celecoxib, proteomic profiling, immunohistochemistry staining method, laboratory biomarker analysis, mass spectrometry
Biological · Drug · Genetic + 1 more
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 19, 2012 · Synced Oct 20, 2026, 10:14 PM EDT
Active, not recruiting Phase 2 Interventional

Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)

NCT05822752
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Budigalimab, Livmoniplimab, Lenvatinib, Sorafenib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
20
States / cities
Prescott Valley, Arizona • Springdale, Arkansas • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Oct 20, 2026, 10:14 PM EDT
Completed Phase 1 Interventional

Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer

NCT02050178
View directory record Official record
Conditions
Pancreatic Cancer, Stage IV Pancreatic Cancer
Interventions
OMP-54F28, Nab-Paclitaxel and Gemcitabine
Drug
Lead sponsor
OncoMed Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
5
States / cities
Los Angeles, California • Aurora, Colorado • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Oct 20, 2026, 10:14 PM EDT
Completed Phase 2 Interventional

Trial of Gemcitabine With or Without Bavituximab in Patients With Previously Untreated Stage IV Pancreatic Cancer

NCT01272791
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
bavituximab, Gemcitabine
Biological · Drug
Lead sponsor
Peregrine Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
15
States / cities
Chandler, Arizona • La Jolla, California • Boca Raton, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Oct 20, 2026, 10:14 PM EDT
Recruiting Phase 3 Interventional

Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial

NCT07271355
View directory record Official record
Conditions
Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Peritoneum, Stage IV Appendix Carcinoma AJCC v8, Stage IVC Colorectal Cancer AJCC v8, Unresectable Colorectal Carcinoma
Interventions
Bevacizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Fluorouracil, Irinotecan Hydrochloride, Leucovorin Calcium, Magnetic Resonance Imaging, Mitomycin, Questionnaire Administration
Biological · Procedure · Drug + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
5
States / cities
Goodyear, Arizona • Duarte, California • Irvine, California + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 20, 2026, 10:14 PM EDT
Terminated Phase 2 Interventional Results available

Everolimus in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Previous Therapy

NCT00390364
View directory record Official record
Conditions
Colorectal Cancer
Interventions
everolimus, antiangiogenesis therapy, biopsy, diagnostic procedure, gene expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, mutation analysis, protein tyrosine kinase inhibitor therapy, reverse transcriptase-polymerase chain reaction
Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2014 · Synced Oct 20, 2026, 10:14 PM EDT
Not listed Phase 2 Interventional

Paclitaxel in Treating Patients With Metastatic, Recurrent, or Unresectable Cancer of the Esophagus

NCT00003326
View directory record Official record
Conditions
Esophageal Cancer
Interventions
paclitaxel
Drug
Lead sponsor
Theradex
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
30
States / cities
Mobile, Alabama • Loma Linda, California • San Francisco, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2008 · Synced Oct 20, 2026, 10:14 PM EDT
Completed Not applicable Interventional Results available

Massage Therapy in Treating the Symptoms of Patients With Locally Advanced or Metastatic Cancer

NCT00253708
View directory record Official record
Conditions
Cancer
Interventions
management of therapy complications, massage therapy, pain therapy, psychosocial assessment and care, quality-of-life assessment
Procedure
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 7, 2017 · Synced Oct 20, 2026, 10:14 PM EDT
Completed Not applicable Interventional

Collection of Patient-Reported Symptoms and Performance Status Via the Internet

NCT00417040
View directory record Official record
Conditions
Prostate Cancer, Breast Cancer, Lung Cancer, Colorectal Cancer, Leukemia, Multiple Myeloma
Interventions
internet-based intervention, assessment of therapy complications, Questionnaire Administration
Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
95
States / cities
Castro Valley, California • Fremont, California • Martinez, California + 63 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2017 · Synced Oct 20, 2026, 10:14 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial

NCT04599140
View directory record Official record
Conditions
Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IIIA Colon Cancer AJCC v8, Stage IIIA Rectal Cancer AJCC v8, Stage IIIB Colon Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8, Stage IIIC Colon Cancer AJCC v8, Stage IIIC Rectal Cancer AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8, Stage IVA Colon Cancer AJCC v8, Stage IVA Rectal Cancer AJCC v8, Stage IVB Colon Cancer AJCC v8, Stage IVB Rectal Cancer AJCC v8, Stage IVC Colon Cancer AJCC v8, Stage IVC Rectal Cancer AJCC v8, Unresectable Colon Adenocarcinoma, Unresectable Rectal Adenocarcinoma
Interventions
CXCR1/2 Inhibitor SX-682, Nivolumab
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 20, 2026, 10:14 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Early Detection of Advanced Adenomas and Colorectal Cancer

NCT06342440
View directory record Official record
Conditions
Colorectal Cancer, Colorectal Neoplasms, Colorectal Polyp, Colorectal Adenocarcinoma, Colorectal Disorders, Colorectal Dysplasia, Colorectal Cancer Stage I, Colorectal Cancer Stage II, Colorectal Cancer Stage III, Colorectal Cancer Stage IV, Colorectal Neoplasms Malignant, Colorectal Serrated Adenocarcinoma, Colorectal Adenoma With Severe Dysplasia, Colorectal Adenoma With Mild Dysplasia, Colorectal Adenoma With Moderate Dysplasia, Colorectal Adenoma and Carcinoma 1, Colorectal Adenomatous Polyp, Colorectal Adenocarcinoma Metastatic in the Liver
Interventions
DENEB
Diagnostic Test
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2028
U.S. locations
2
States / cities
Monrovia, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 20, 2026, 10:14 PM EDT
Completed Not applicable Interventional

Diet Education Program for Stage I-IV Colorectal Cancer Survivors

NCT04597151
View directory record Official record
Conditions
Stage I Colorectal Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage IIA Colorectal Cancer AJCC v8, Stage IIB Colorectal Cancer AJCC v8, Stage IIC Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions
Dietary Intervention
Dietary Supplement
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 9, 2023 · Synced Oct 20, 2026, 10:14 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer

NCT01647828
View directory record Official record
Conditions
Stage IV Pancreatic Cancer
Interventions
OMP-59R5, Gemcitabine, Placebo, Nab-Paclitaxel
Drug
Lead sponsor
OncoMed Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
26
States / cities
Goodyear, Arizona • Bakersfield, California • Fullerton, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Oct 20, 2026, 10:14 PM EDT
Terminated Phase 1 Interventional

Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer

NCT00937482
View directory record Official record
Conditions
Male Breast Cancer, Stage IV Breast Cancer, Stage IV Melanoma, Stage IV Non-small Cell Lung Cancer, Stage IV Renal Cell Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer, Tumors Metastatic to Brain
Interventions
cediranib maleate, whole-brain radiation therapy
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 8, 2013 · Synced Oct 20, 2026, 10:14 PM EDT
Recruiting Phase 1 Interventional

AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer

NCT07619313
View directory record Official record
Conditions
Borderline Resectable Pancreatic Ductal Adenocarcinoma, Locally Advanced Cholangiocarcinoma, Locally Advanced Pancreatic Adenocarcinoma, Metastatic Cholangiocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions
Biopsy Procedure, Cisplatin, Computed Tomography, Durvalumab, Fluorouracil, Gemcitabine, Irinotecan, Leucovorin, Ligritinib, Magnetic Resonance Imaging, Oxaliplatin, Zimberelimab
Procedure · Drug · Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 20, 2026, 10:14 PM EDT
Completed Phase 1 Interventional

TAS-102 and Radiation Therapy in Treating Patients With Rectal Cancer That Is Locally Recurrent, Metastatic, or Cannot Be Removed by Surgery

NCT03297710
View directory record Official record
Conditions
Rectal Adenocarcinoma, Recurrent Rectal Carcinoma, Stage IV Rectal Cancer AJCC v7, Stage IVA Rectal Cancer AJCC v7, Stage IVB Rectal Cancer AJCC v7
Interventions
Quality-of-Life Assessment, Radiation Therapy, Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102
Other · Radiation · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 5, 2023 · Synced Oct 20, 2026, 10:14 PM EDT
Completed Early Phase 1 Interventional

Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer

NCT00436410
View directory record Official record
Conditions
Adrenocortical Carcinoma, Breast Cancer, Colorectal Cancer, Gastrointestinal Cancer, Kidney Cancer, Liver Cancer, Melanoma (Skin), Ovarian Cancer, Pancreatic Cancer, Sarcoma
Interventions
colloidal gold-bound tumor necrosis factor, electron microscopy, pharmacological study, conventional surgery
Biological · Other · Procedure
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 2, 2012 · Synced Oct 20, 2026, 10:14 PM EDT
Completed Phase 2 Interventional Results available

2 Phase Comparison of Pre-operative CT and PET Images for Metastatic Colorectal Cancer

NCT01821105
View directory record Official record
Conditions
Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV A Bladder Cancer, Stage IV A Rectal Cancer, Stage IV B Colon Cancer, Stage IV B Rectal Cancer
Interventions
PET Scan, CT Scan, fludeoxyglucose F 18, computer-aided detection/diagnosis
Procedure · Radiation
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 2, 2016 · Synced Oct 20, 2026, 10:14 PM EDT
Completed Not applicable Interventional

Biological Therapy in Treating Patients With Advanced Cancer

NCT00005956
View directory record Official record
Conditions
Breast Cancer, Gastric Cancer, Ovarian Cancer
Interventions
HER-2/neu intracellular domain protein, therapeutic autologous dendritic cells
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 9, 2014 · Synced Oct 20, 2026, 10:14 PM EDT